Ruxolitinib: A Novel Molecule in the Management of Dermatological Disorders

February 2026 in “ Indian Journal of Skin Allergy ”

Shreya Datta, Sushil Kumar Singh, Disha Chakraborty, Abhishek De, Sandipan Dhar

ruxolitinib JAK 1 and 2 inhibitor alopecia areata atopic dermatitis non-segmental vitiligo

Studysummary This article reviews the clinical efficacy of Ruxolitinib cream for skin conditions, reporting significant improvements in atopic dermatitis and vitiligo, with minimal systemic absorption and a favorable safety profile, compared to placebo.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on skinallergyjournal.com →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research The Use of Topical Ruxolitinib 1.5% Cream in Frontal Fibrosing Alopecia: A Case Report

6 citations , May 2024 in “JAAD Case Reports”

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

4 citations , April 2024 in “Journal of Drugs in Dermatology”

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.